在创新药牛市催生的资本盛宴中,CRO行业龙头借力打力,将“以投养研”做成新引擎,红利持续兑现。7月17日,泰格医药发布公告称,旗下投资平台杭州泰格股权投资合伙企业将以约3411万美元(约合人民币2.47亿元)的价格,将其持有的礼新医药3.41%股权出售给正大制药投资(北京)集团有限公司。这笔交易源于中国生物制药日前宣布拟以不超过9.51亿美元收购礼新医药95.09%的股权。作为礼新医药的早期投资者...
Source Link在创新药牛市催生的资本盛宴中,CRO行业龙头借力打力,将“以投养研”做成新引擎,红利持续兑现。7月17日,泰格医药发布公告称,旗下投资平台杭州泰格股权投资合伙企业将以约3411万美元(约合人民币2.47亿元)的价格,将其持有的礼新医药3.41%股权出售给正大制药投资(北京)集团有限公司。这笔交易源于中国生物制药日前宣布拟以不超过9.51亿美元收购礼新医药95.09%的股权。作为礼新医药的早期投资者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.